cyt005-allqbg10
Allergenexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2005 (NCT00652223)
Timeline
Indications
Mechanism of action
- Peptidase 1Immunity, desensitized
DERF1 immunity, desensitized
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cyt005-allqbg10
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00574223 | Phase 2 | Nov 1, 2007 | Cytos Biotechnology AG |
| NCT00574704 | Phase 2 | Sep 1, 2006 | Cytos Biotechnology AG |
| NCT00293904 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2006 | Cytos Biotechnology AG, University of Zurich |
| NCT00652223 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2005 | Cytos Biotechnology AG |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cytos Biotechnology AG | For profit | 4 | 4 | 1 | 2005 |
| University of Zurich | Academic/Hospital | 1 | 0 | 1 | 2006 |
2 organizations
Page 1 / 1